Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results, Beats Estimates By $0.08 EPS

Recursion Pharmaceuticals (NASDAQ:RXRX) issued its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08, FiscalAI reports. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The firm had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. During the same quarter in the previous year, the company earned ($0.50) earnings per share. The business’s revenue for the quarter was down 56.8% on a year-over-year basis.

Here are the key takeaways from Recursion Pharmaceuticals’ conference call:

• REC-4881: Company-reported clinical proof-of-concept in FAP showing significant reductions in precancerous polyps with durable responses, and ongoing FDA engagement to define a potential registrational path.
• REC-1245 (RBM39 degrader): Early DAHLIA Phase I data from 16 patients report no dose-limiting toxicities, PD-confirmed target engagement and PK supportive of daily dosing, with more dose-escalation and fuller PK/PD readouts expected in H2.
• REC-4539 (LSD1 inhibitor): First patient dosed in Phase I for a molecule designed to reduce thrombocytopenia risk and that is brain-penetrant; initial PK and safety data are expected in H2 2027.
• Platform and model advances (TxPert, TxFM) and company-reported efficiency claims — e.g., >50 PB of multimodal data, ~90% fewer compounds synthesized and ~2x faster progress to development candidates — are being deployed but remain company-reported metrics to be independently validated by future outcomes.
• Financial position: $665M in cash, asserted runway into early 2028, a 30% year-over-year reduction in operating expenses, and 2026 cash OpEx guidance under $390M, which management says funds near-term milestones without additional financing.

Recursion Pharmaceuticals Trading Up 1.8%

RXRX stock traded up $0.06 during trading hours on Wednesday, reaching $3.43. The stock had a trading volume of 17,640,137 shares, compared to its average volume of 11,427,391. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.50. The stock has a 50-day simple moving average of $3.40 and a 200 day simple moving average of $4.16. Recursion Pharmaceuticals has a fifty-two week low of $2.80 and a fifty-two week high of $7.18.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 28,298 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $3.35, for a total value of $94,798.30. Following the transaction, the chief executive officer directly owned 2,262,085 shares in the company, valued at $7,577,984.75. The trade was a 1.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ben R. Taylor sold 7,956 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total transaction of $26,970.84. Following the completion of the transaction, the chief financial officer owned 1,180,318 shares in the company, valued at approximately $4,001,278.02. This represents a 0.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 79,680 shares of company stock worth $256,121 over the last quarter. 8.43% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 28.1% in the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after acquiring an additional 2,428 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Recursion Pharmaceuticals in the third quarter valued at about $61,000. RPO LLC acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $62,000. Daiwa Securities Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 29.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock valued at $64,000 after acquiring an additional 2,883 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $65,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RXRX has been the topic of a number of research reports. JPMorgan Chase & Co. cut their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Bank of America cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $9.20.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.